Global Information
회사소개 | 문의 | 비교리스트

신경내분비종양 : 파이프라인 리뷰

Neuroendocrine Tumors (Oncology) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 12월 상품코드 237878
페이지 정보 영문 1317 Pages 배송안내
가격
US $ 2,500 ₩ 3,179,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 6,358,000 PDF (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,500 ₩ 9,537,000 PDF (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


신경내분비종양 : 파이프라인 리뷰 Neuroendocrine Tumors (Oncology) - Drugs in Development, 2021
발행일 : 2021년 12월 페이지 정보 : 영문 1317 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

신경내분비종양은 내분비계 호르몬 산생세포로부터 발현하는 것으로 고혈당, 설사, 식욕 감퇴/체중 저하, 몸 일부의 비대 또는 응어리, 황달, 두통, 불안신경증, 위궤양 등의 증상이 있습니다. 치료에는 수술, 방사선 치료, 화학요법 등이 있습니다.

세계의 신경내분비종양(Neuroendocrine Tumors) 치료용 파이프라인 제품에 대해 조사했으며, 현재 개발 파이프라인 상황과 최신 동향, 후기 단계 및 중지된 프로젝트, 주요 기업과 개발중인 제품 리뷰 등의 정보를 전해드립니다.

서론

  • 조사 범위

신경내분비종양 개요

치료제 개발

  • 파이프라인 제품 개요
  • 파이프라인 제품 비교 분석

신경내분비종양 : 기업에서 개발중인 치료제

신경내분비종양 : 대학/연구기관에서 연구중인 치료제

신경내분비종양 : 파이프라인 제품 개요

  • 후기 단계 제품
  • 임상 단계 제품
  • 초기 단계 제품

신경내분비종양 : 기업에서 개발중인 제품

신경내분비종양 : 대학/연구기관에서 연구중인 제품

신경내분비종양 : 치료제 개발에 참여하고 있는 기업

  • Advanced Accelerator Applications S.A.
  • Aegis Therapeutics, LLC
  • Amgen Inc.
  • AVEO Pharmaceuticals, Inc.
  • Boehringer Ingelheim GmbH
  • Chiasma, Inc.
  • Crinetics Pharmaceuticals, Inc.
  • Daiichi Sankyo Company, Limited
  • Delcath Systems, Inc.
  • DexTech Medical AB
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • Foresee Pharmaceuticals, LLC
  • Hutchison MediPharma Limited
  • Intezyne, Inc
  • INVENT Pharmaceuticals, Inc.
  • Ipsen S.A.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Karyopharm Therapeutics, Inc.
  • Lexicon Pharmaceuticals, Inc.
  • Midatech Pharma Plc .
  • Millennium Pharmaceuticals, Inc.
  • MolMed S.p.A.
  • Northwest Biotherapeutics, Inc.
  • Novartis AG
  • OctreoPharm Sciences GmbH
  • OXiGENE, Inc.
  • Peptron, Inc.
  • Pfizer Inc.
  • Pharma Mar, S.A.
  • Progenics Pharmaceuticals, Inc.
  • Provectus Biopharmaceuticals, Inc.
  • Sompharmaceuticals S.A.
  • Strongbridge Biopharma plc
  • Vascular Biogenics Ltd.

신경내분비종양 : 치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

약제 개요

신경내분비종양 : 최근의 파이프라인 동향

신경내분비종양 : 휴지중인 프로젝트

신경내분비종양 : 중지 프로젝트

신경내분비종양 : 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

도표

KSM 16.07.11

List of Tables

List of Tables

  • Number of Products under Development for Neuroendocrine Tumors, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Neuroendocrine Tumors - Dormant Projects, 2021
  • Neuroendocrine Tumors - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Neuroendocrine Tumors, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuroendocrine Tumors - Drugs In Development, 2021, provides an overview of the Neuroendocrine Tumors (Oncology) pipeline landscape.

Neuroendocrine tumor begins in the hormone-producing cells of the body's neuroendocrine system, which is made up of cells that are a cross between traditional endocrine cells (or hormone-producing cells) and nerve cells. Symptom includes hyperglycemia, diarrhea, loss of appetite/weight loss, thickening or lump in any part of the body, jaundice, headache, anxiety, and gastric ulcer disease. Treatments include surgery, radiation therapy and chemotherapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuroendocrine Tumors - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Neuroendocrine Tumors (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuroendocrine Tumors (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroendocrine Tumors and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 4, 43, 38, 2, 14, 5 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Discovery stages comprises 1, 2 and 1 molecules, respectively.

Neuroendocrine Tumors (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neuroendocrine Tumors (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Neuroendocrine Tumors (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neuroendocrine Tumors (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neuroendocrine Tumors (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neuroendocrine Tumors (Oncology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neuroendocrine Tumors (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neuroendocrine Tumors (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Neuroendocrine Tumors - Overview
  • Neuroendocrine Tumors - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Neuroendocrine Tumors - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Neuroendocrine Tumors - Companies Involved in Therapeutics Development
  • Neuroendocrine Tumors - Drug Profiles
  • Neuroendocrine Tumors - Dormant Projects
  • Neuroendocrine Tumors - Discontinued Products
  • Neuroendocrine Tumors - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q